Designing point-of-care molecular tests for emerging biological threats
Emerging biological threats create a need for rapid development of molecular diagnostics. Identifying suitable pathogen targets and translating them into effective tests requires specialised research and experimental validation, making diagnostic development a challenge when responding to new threats.
AminoAnalytica designs point-of-care molecular diagnostics for emerging biological threats. Its Amina research project uses an autonomous AI scientist for rapid pathogen diagnostic design, with support from ARIA's AI Scientists programme.
What stands out about AminoAnalytica
ARIA supports Amina's rapid pathogen diagnostic design project through its AI Scientists programme; the company allocation is undisclosed.
Selected for Y Combinator's Summer 2024 batch, as recorded in YC's company directory and corroborated by Imperial.
Won the AI and Robotics track of Imperial's Venture Catalyst Challenge in 2024, securing £10,000 in prize funding.
Launched Amina’s no-code protein-engineering software in July 2025, integrating more than 50 specialised tools.
Published enzyme-design research benchmarks embedding energy against existing enzyme activity data and molecular-dynamics simulations.
Co-founders Adam Wu and Abhi Rajendran co-authored peer-reviewed research on language-model-guided enzyme design in PLOS Computational Biology.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.